Back to results
US 8,999,638 B2Granted
Method of treatment based on polymorphisms of the KCNQ1 gene
AssigneeVanda Pharmaceuticals Inc.
InventorsCurt D. Wolfgang, Mihael H. Polymeropoulos
Life of this patent
Estimating the term…
Abstract
The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.
Claims15
A method of administering iloperidone or a metabolite thereof to a human individual, the method comprising:
- determining or having determined the individual's KCNQ1 genotype at position 79764 of SEQ. ID. 1;
- and
- in the case that the individual's KCNQ1 genotype at position 79764 of SEQ. ID. 1 is associated with an increased risk of QT prolongation, administering to the individual a first quantity of iloperidone or a metabolite thereof, and
- in the case that the individual's KCNQ1 genotype at position 79764 of SEQ. ID. 1 is not associated with an increased risk of QT prolongation, administering to the individual a second quantity of iloperidone or a metabolite thereof, wherein the first quantity is less than the second quantity,
- wherein the KCNQ1 genotype associated with an increased risk of QT prolongation is GG at position 79764 of SEQ. ID. 1, and the KCNQ1 genotype not associated with an increased risk of QT prolongation is non-GG at position 79764 of SEQ. ID. 1.
2 more elements
A method of treating a human individual with iloperidone or a metabolite thereof, the method comprising:
- characterizing an expression product of the individual's KCNQ1 gene;
- and
- in the case that the characterized expression product corresponds to a KCNQ1 genotype of GG at position 79764 of SEQ. ID. 1, administering to the individual a first quantity of iloperidone or a metabolite thereof, and
- in the case that the characterized expression product corresponds to a KCNQ1 genotype of non-GG at position 79764 of SEQ. ID. 1, administering to the individual a second quantity of iloperidone or a metabolite thereof,
- wherein the first quantity is less than the second quantity.
2 more elements
A method of administering iloperidone or a metabolite thereof to a human individual suffering from long QT syndrome (LQTS), the method comprising:
- determining or having determined the individual's KCNQ1 genotype at position 79764 of SEQ. ID. 1;
- and
- administering to the individual a quantity of the iloperidone or the metabolite thereof based on the individual's KCNQ1 genotype at position 79764 of SEQ. ID. 1,
- wherein a first quantity is administered to the individual in a case in which the individual has a KCNQ1 genotype of GG at position 79764 of SEQ. ID. 1, and a second quantity is administered to the individual in a case in which the individual has a KCNQ1 genotype that is non-GG at position 79764 of SEQ. ID. 1.
1 more element
Dependencies are inferred from the claim text.